Bordetella pertussis Antibody, IgG by Immunoblot
Also known as: BORDG BLOT
Use
The Bordetella pertussis Antibody, IgG by Immunoblot test is utilized to provide evidence of prior vaccination or past infection with Bordetella pertussis. It is not intended to determine immunity levels to B. pertussis. For acute pertussis diagnosis, the CDC recommends using Bordetella pertussis/parapertussis PCR or Culture tests as the first-line tests. This immunoblot is useful in assessing late-stage pertussis infections. Detection of IgG antibodies against specific pertussis antigens indicates a past exposure or vaccination.
Special Instructions
This assay specifically tests for the presence of pertussis toxin (PT), pertussis toxin PT 100 (PT-100), and filamentous hemagglutinin antibody (FHA).
Limitations
This test cannot determine immunity to B. pertussis. Negative results may occur if the antibody titer is too low to detect. The assay only identifies IgG antibodies specific to Bordetella pertussis and does not differentiate between vaccine-induced and infection-induced antibodies. High antibody titers may suggest recent infection or vaccination but do not confirm immunity.
FDA ApprovedNew York Approved
Methodology
Immunoassay (Western Blot)
Biomarkers
LOINC Codes
- 93479-4
- 69754-0
- 69755-7
- 74766-7
Result Turnaround Time
1-4 days
Related Documents
For more information, please review the documents below
Specimen
Serum
Volume
1 mL
Minimum Volume
0.15 mL
Container
ARUP Standard Transport Tube
Collection Instructions
Separate serum from cells ASAP or within 2 hours of collection.
Storage Instructions
Refrigerated
Causes for Rejection
Heat-inactivated specimens.
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 48 hours |
| Refrigerated | 2 weeks |
| Frozen | 1 year |